



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 29 Jan 2020 (#4)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notice

- [NOT-OD-20-060](#) Update of NIH Continuous Submission Policy: Change in Submission Deadlines and End of Recent Substantial Service Option. This Notice alerts the scientific research community of plans to discontinue the practice of granting one-year continuous submission status to reviewers with recent substantial review service, which was earned by serving 6 times in an 18 month period.

1. Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-092](#)

Type: UG3/UH3

Application Due Date: Applications will be accepted on a rolling basis, beginning on February 24, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement is to support the discovery and development of medications to prevent and treat opioid use disorders (OUD) and overdose. The UG3/UH3 Phased Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Application may include preclinical or clinical research studies that will have high impact and quickly yield the necessary results to advance closer to FDA approval medications that are safe and effective to prevent and treat OUDs and overdose. The compounds to be evaluated can be small molecules or biologics. They can be tested in pre-clinical models and/or for the clinical manifestations of OUDs such as withdrawal, craving, relapse, or overdose. Applications may focus on the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications that hold promise for the treatment of OUDs and overdose. Through this FOA, NIDA seeks to fast-track the discovery and development of medications to prevent and treat OUDs or opioid overdose and to advance them in the FDA's drug development approval pipeline. This project is part of the NIH initiative to establish a public-private partnership to address the opioid crisis via more effective and safe ways to prevent and treat opioid use disorders and overdose. <https://www.nih.gov/opioid-crisis>

Budget: Application budgets are limited to \$3million per year for direct costs. The maximum period of support is 5 years.

2. Genomic Community Resources (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-100](#)

Type: U24

Application Due Date: [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: To facilitate genomic research and the dissemination of products, NHGRI supports genomic resources that are crucial for basic research, disease studies, model organism studies, and other biomedical research. Awards under this FOA will support the development and distribution of genomic resources that use cost-effective approaches and will be valuable for the broad research community. Such resources include (but are not limited to) databases and informatics resources (such as human and model organism databases, ontologies, and analysis toolsets), comprehensive identification and collections of genomic features (such as functional genomic elements), and standard data types produced using central sets of samples (such as structural variants in 1000 Genomes or GTEx samples).

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

3. Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-CA-20-007](#)

Type: R21

Application Due Date: June 9, 2020; November 18, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods that can considerably improve acquisition, management, analysis, and

dissemination of relevant data and/or knowledge. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, there must be a clear rationale for how the proposed informatics method or algorithm is novel and how it will benefit the cancer research field. Potential applicants who are interested in downstream technology development, from prototyping to hardening and adaptation, should consult the other companion FOAs listed above. **Budget:** NCI intends to commit \$1,240,000 in FY 2021 to fund 6 awards. Direct costs are limited to \$275,000 over a two year period. No more than \$200,000 may be requested in any single year. The maximum project period is two years.

4. Early-Stage Development of Informatics Technologies for Cancer Research and Management (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-CA-20-008](#)

Type: U01

Application Due Date: June 9, 2020; November 18, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.

Budget: NCI intends to commit \$2,250,000 in FY 2021 to fund 5-6 awards. Budgets are limited to \$300,000 Direct Costs (excluding consortium F&A) per year. The maximum project period is three years.

5. Advanced Development of Informatics Technologies for Cancer Research and Management (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-CA-20-009](#)

Type: U24

Application Due Date: June 09, 2020; November 18, 2020 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included. Potential applicants who are interested in early-stage development or informatics resource sustainment should consult the companion FOAs listed above.

Budget: NCI intends to commit \$3,600,000 in FY 2021 to fund 4 awards. Budgets are limited to \$600,000 Direct Costs (excluding consortium F&A) per year. The maximum project period is five years.

6. Sustained Support for Informatics Technologies for Cancer Research and Management (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-CA-20-010](#)

Type: U24

Application Due Date: June 09, 2020; November 18, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR FOAs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justification for why the research resource should be maintained and how it has benefitted and will continue to benefit the cancer research field. In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and deep engagement between the resource and the targeted research community should be described.

Budget: NCI intends to commit \$2,250,000 in FY 2021 to fund 2 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105